Bafna Pharmaceuticals
- Market cap
- ₹ 1,064 Cr.
- P/E
- 33.9x
- P/B
- 11.12x
- 52-week range
- 94.77 – 479.95
- ROE
- 12%
- ROCE
- 12%
- Dividend yield
- 0%
- Debt / equity
- 0.39
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bafna Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)33.9 against a typical 34.6: cheaper than most peers (1st = cheapest).108th of 220
- Sales growth−23.2% against a typical +15.6% from a year earlier.178th of 197
- Profit growth−97.6% against a typical +18.9% from a year earlier.148th of 160
- Share price, 3 months+78.7% against a typical −0.5%.5th of 200
- Size₹ 1,064.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).85th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BB+ by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]BB+ | Positive | 23 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 23 Jan 2026 | Reaffirmed | [ICRA]BB+ | — | ICRA | ₹ 55 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the Un-Audited financial results for the Quarter ended June 30, 2026 |
| 29 May 2026 | Financial Results | To consider and approve the Audited Financial Results for the Quarter and Year ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider and approve the Unaudited Financial Results for the Quarter ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the Un-audited financial results for the Quarter and Half Year ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the Un-audited Financial Results for the Quarter ended Jun 30, 2025 |
| 26 May 2025 | Financial Results | To consider and approve the Audited Financial Results for the Quarter & Year ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41 | 28 | 41 | 33 | 40 | 33 | 39 | 35 | 35 | 38 | 42 | 27 |
| Expenses | 37 | 31 | 39 | 32 | 37 | 30 | 36 | 30 | 31 | 35 | 39 | 26 |
| Operating Profit | 4 | −2 | 3 | 1 | 4 | 3 | 3 | 5 | 4 | 3 | 4 | 1 |
| OPM % | 9.9% | −7.3% | 7% | 3.6% | 9.4% | 9.2% | 8% | 14.6% | 12.1% | 8% | 8.4% | 3.4% |
| Other Income | 0 | 1 | 1 | 0 | 1 | 0 | −1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | 2 | −3 | 1 | −1 | 3 | 1 | 1 | 3 | 3 | 2 | 3 | 0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | −5% | 0% |
| Net Profit | 2 | −3 | 1 | −1 | 3 | 1 | 1 | 3 | 3 | 2 | 3 | 0 |
| EPS in Rs | 1.05 | −1.24 | 0.62 | −0.3 | 1.11 | 0.4 | 0.55 | 1.43 | 1.32 | 0.78 | 1.16 | 0.03 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 16%
- 3 Years
- 9%
- TTM
- −3%
- 10 Years
- 11%
- 5 Years
- 14%
- 3 Years
- 0%
- TTM
- −23%
- 10 Years
- 24%
- 5 Years
- 12%
- 3 Years
- 31%
- TTM
- —
- 10 Years
- −6%
- 5 Years
- 11%
- 3 Years
- 10%
- TTM
- —
Peers
Listed companies in the same business.
| Bafna Pharmaceuticals | ₹ 451.60 | ₹ 1,064 Cr. | 33.9x | 11.1x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Bafna Mahaveer Chand
- Chief Executive Officer
- Melagiri Sridhar
- Chief Financial Officer
- Mohanachandran A. Vishnu Vasudeva Kuppa
- Compliance Officer, Company Secretary
- Vinayak Dinesh Dendukuri
- Whole Time Director - Quality
- Shanmugam Hemalatha
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.